Загрузка...
The role of B cells in multiple sclerosis: current and future therapies
While it was long held that T cells were the primary mediators of multiple sclerosis (MS) pathogenesis, the beneficial effects observed in response to treatment with Rituximab, a monoclonal antibody (mAb) targeting CD20, shed light on a key contributor to MS that had been previously underappreciated...
Сохранить в:
| Опубликовано в: : | Cell Immunol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6540809/ https://ncbi.nlm.nih.gov/pubmed/31130183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cellimm.2018.10.006 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|